MDxHealth (MDXH) to Release Earnings on Thursday

MDxHealth (NASDAQ:MDXH) will likely be releasing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect MDxHealth to post earnings of ($0.13) per share and revenue of $26.0540 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

MDxHealth Trading Down 0.6%

MDXH stock opened at $3.61 on Tuesday. The firm has a market cap of $178.70 million, a PE ratio of -5.64 and a beta of 1.64. MDxHealth has a 1 year low of $1.35 and a 1 year high of $5.33. The company has a fifty day simple moving average of $3.52 and a 200 day simple moving average of $3.75.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on MDXH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th. BTIG Research restated a “buy” rating and set a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. TD Cowen upped their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Lake Street Capital increased their target price on shares of MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, MDxHealth presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

Institutional Trading of MDxHealth

Hedge funds have recently added to or reduced their stakes in the business. Intesa Sanpaolo Wealth Management bought a new position in MDxHealth in the fourth quarter valued at approximately $36,000. Lido Advisors LLC bought a new stake in shares of MDxHealth during the third quarter worth $48,000. Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth during the third quarter worth $53,000. Squarepoint Ops LLC bought a new stake in MDxHealth in the 4th quarter valued at $51,000. Finally, Bank of America Corp DE lifted its position in MDxHealth by 5,164.0% in the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock valued at $70,000 after acquiring an additional 14,769 shares in the last quarter.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.